

Buprenorphine Waiver Training

2019 OPAT Preconference Workshop

Wednesday, May 29, 2019

8:00 a.m. – 12:30 p.m.

Presenters:

Todd Korthuis, MD, MPH

Professor/Physician

Oregon Health & Science University

Jessica Gregg, MD, PhD

Associate Professor/Physician

Oregon Health & Science University

Learning Objectives:

- Describe the components of evaluation for medication assisted treatment
- Discuss the range of treatment goals for patients with OUD
- Identify the FDA-approved pharmacological treatments for OUD
- Demonstrate an understanding of the benefits and limitations of all available treatments and differences between them
- Describe the different first and second-line approaches to treat OUD and the process of shared decision making

Target Audience: This activity will assist physicians and physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders

Description:

This training will help clinicians understand the mechanism and rationale for buprenorphine treatment, selection of patients that are appropriate for buprenorphine treatment and buprenorphine initiation and maintenance procedures. The course is provided in a “Half and Half” format, which means the first part is taken in person and the second part, for physicians, PAs and APRNs, is completed on-line.

The 4.25 hour in-person portion of the course is open to interested practitioners who are involved in serving patients receiving medication assisted treatment for OUD (nurses, counselors, social workers, pharmacists, etc.), as well as physicians, PAs, and APRNs. The 3.5 hour on-line portion completes the 8-hour training requirement for physicians. For PAs and APRNs, an additional 16 hours training is required to meet the 24 hour training requirement for the waiver (see <https://pcssnow.org/education-training/mat-training/>).

After completing the in-person training, eligible participants will be emailed instructions for the on-line portion of the course. Those who have successfully completed the course (both on-line and live) are eligible to apply to the US Substance Abuse and Mental Health Services Administration (SAMHSA) to obtain a waiver to prescribe buprenorphine.

Accreditation: 4.25 AMA PRA Category 1 Credits™

Cost: Free

The American Academy of Addiction Psychiatry is the Data Sponsor for this training.

Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.